BCMA CAR-T cells
Phase 2Cell therapy
BCMA CAR-T cells is one of 39 biologic programs targeting Myeloma. It is currently in Phase 2.
2
Indications
8
Total Trials
3
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Vepesid
AAvyxa
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Busulfex
Akero TherapeuticsPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Mezigdomide
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma7 trials
Show 4 more trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BCMA CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details